FY28 SBIR Contract Topic: Development and Production of Adjuvant Mimics for Vaccines for Infectious, Allergic, and Immune-Mediated Diseases
Forecast New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $3,000,000 to $7,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) forecasts a new FY28 SBIR contract for the development and production of adjuvant mimics for vaccines for infectious, allergic, and immune-mediated diseases, with solicitation release estimated for January 1, 2028 and award estimated for June 1, 2028. The topic solicits SBIR R&D proposals on developing mimics of late-stage inaccessible adjuvants to increase the availability of promising adjuvants for safe and effective future vaccines. The forecast is set aside for Total Small Business and classified under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The estimated award value range is $3 million to $7 million. Contracting Officer Callie Prassinos (callie.prassinos@nih.gov, +1 240-669-5155) and Aaron Joffe (ari.joffe@nih.gov) are the listed points of contact at NIH.
Forecast text
This request is for inclusion of a FY28 SBIR Contract topic entitled: "Development and Production of Adjuvant Mimics for Vaccines for Infectious, Allergic, and Immune-Mediated Diseases". This contract topic will solicit SBIR R&D proposals on subjects relevant to development of mimics of late-stage inaccessible adjuvants. The purpose of this proposal is to increase the availability of promising adjuvants that can be used in safe and effective vaccines in the future. If this request is not approved, NIAID will not be able to solicit the development of novel adjuvants from small buisinesses, which will ultimately limit progress on improved vaccines and the NIH's ability to support small buisinesses via the SBIR program.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast